William Blair Weighs in on Elanco Animal Health Incorporated’s Q2 2022 Earnings (NYSE:ELAN)

Elanco Animal Health Incorporated (NYSE:ELANGet Rating) – Equities researchers at William Blair cut their Q2 2022 earnings estimates for Elanco Animal Health in a report released on Monday, May 9th. William Blair analyst J. Kreger now expects that the company will post earnings per share of $0.25 for the quarter, down from their previous forecast of $0.31. William Blair also issued estimates for Elanco Animal Health’s Q3 2022 earnings at $0.26 EPS, FY2022 earnings at $1.17 EPS, Q1 2023 earnings at $0.56 EPS, Q2 2023 earnings at $0.34 EPS, Q4 2023 earnings at $0.36 EPS and FY2023 earnings at $1.60 EPS.

Several other research firms also recently commented on ELAN. Zacks Investment Research downgraded Elanco Animal Health from a “hold” rating to a “sell” rating in a research note on Tuesday. Barclays raised their target price on Elanco Animal Health from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Monday, February 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $38.43.

Elanco Animal Health stock opened at $21.90 on Wednesday. The company has a current ratio of 1.99, a quick ratio of 1.16 and a debt-to-equity ratio of 0.80. The firm has a market cap of $10.36 billion, a PE ratio of -22.81, a P/E/G ratio of 1.06 and a beta of 0.74. The stock’s 50 day simple moving average is $26.03 and its two-hundred day simple moving average is $27.77. Elanco Animal Health has a 12 month low of $21.59 and a 12 month high of $37.49.

Elanco Animal Health (NYSE:ELANGet Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.01. Elanco Animal Health had a positive return on equity of 6.59% and a negative net margin of 9.91%. The business had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the previous year, the firm earned $0.37 earnings per share. The company’s revenue was down 1.4% on a year-over-year basis.

In other Elanco Animal Health news, Director R David Hoover bought 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The stock was purchased at an average cost of $28.66 per share, for a total transaction of $143,300.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.40% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of ELAN. AMG National Trust Bank boosted its holdings in Elanco Animal Health by 24.0% in the first quarter. AMG National Trust Bank now owns 44,971 shares of the company’s stock valued at $1,173,000 after purchasing an additional 8,702 shares during the last quarter. AGF Investments LLC raised its position in shares of Elanco Animal Health by 19.3% during the 1st quarter. AGF Investments LLC now owns 31,582 shares of the company’s stock worth $824,000 after purchasing an additional 5,116 shares during the period. AGF Investments America Inc. grew its holdings in Elanco Animal Health by 91.1% in the 1st quarter. AGF Investments America Inc. now owns 139,056 shares of the company’s stock worth $3,628,000 after buying an additional 66,304 shares in the last quarter. Academy Capital Management Inc. TX grew its holdings in Elanco Animal Health by 0.5% in the 1st quarter. Academy Capital Management Inc. TX now owns 1,075,769 shares of the company’s stock worth $28,067,000 after buying an additional 4,929 shares in the last quarter. Finally, Hedges Asset Management LLC bought a new position in Elanco Animal Health in the 1st quarter worth approximately $731,000.

Elanco Animal Health Company Profile (Get Rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Featured Stories

Earnings History and Estimates for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.